F9 and hemophilia: A number of strategies to refine gene therapy for haemophilia are currently being investigated notably a switch to the use of AAV8 serotype vectors, and subsequent modifications to vector design such as i) increasing the specific activity of the factor IX (FIX) expressed by introduction of favourable sequence variants and ii) improved manufacture methods to reduce the level of empty capsids and hence the immunogenic load.